EU for Evibodies

By Kate McDonald
Monday, 09 February, 2009

Arana Therapeutics has been granted an EU patent for its Evibodies range of small antibodies.

Evibodies were part of the technology platform brought into the company by EvoGenix when it merged with Peptech in 2007.

Evibodies are small fragments of a family of proteins that act like antibodies but are about one-tenth smaller.

They were given a US patent in 2007.

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...

Content from other channels on our network

National Pain Alliance launched to advocate for chronic pain

Sexual misconduct findings added to public register under "landmark reforms"

Australia invests further $14.6 million in national allergy research

Can seasonal influenza vaccination prime the immune system for future strains?

"Targeted supports" launched for former patients of Simon Gordon

Cargill expands its edible oil facility in Malaysia

Mitigating unseen losses in large food packs

Perfect Automation and Omori have joined forces with packaging solutions

Fonterra names Richard Allen as new CEO

Food packaging testing supports Atlantic crossing victory

Call for 10c increase on container return schemes

Water transition key at Global Water Summit 2026

CCEP Australia strengthens producer responsibility

Veolia ANZ appoints new CEO

Map reveals hidden UV risk for next-gen solar panels